Camrelizumab With AC in Patients With Brain Metastases of Driven Gene-negative,NSCLC

Summary

The primary hypothesis is that camrelizumab in combination with pemetrexed/ carboplatin will present a better efficacy for treatment of first line metastatic non-squamous non-small cell lung cancer and minimize the risk of toxicity

Timeline

Start

2020-01-15

Primary completion

2022-08-30

Completion

2022-12-30

Publications

• Hou X, Zhou C, Wu G, Lin W, Xie Z, Zhang H, Yi J, Lv J, Cheng F, She F, Chen L. First-line camrelizumab plus pemetrexed and carboplatin for advanced non-squamous non-small-cell lung cancer with brain metastases (CAP-BRAIN): final results of a multicentre, open-label, single-arm, phase 2 trial in China. EClinicalMedicine. 2025 Nov 12;90:103638. doi: 10.1016/j.eclinm.2025.103638. eCollection 2025 Dec.
• Li M, Chen J, Yu H, Zhang B, Hou X, Jiang H, Xie D, Chen L. Cerebrospinal fluid immunological cytokines predict intracranial tumor response to immunotherapy in non-small cell lung cancer patients with brain metastases. Oncoimmunology. 2023 Dec 7;13(1):2290790. doi: 10.1080/2162402X.2023.2290790. eCollection 2024.

Drugs

Indications